Zobrazeno 1 - 10 of 65 pro vyhledávání: '"Albert Császár"'
1
Akademický článek
The characteristics of two LDL-cholesterol level reduction treatment strategies, 'treat-to-target' and 'percent reduction': an observational study without intervention
Autor: Albert Császár
Publikováno v: BMC Cardiovascular Disorders, Vol 19, Iss 1, Pp 1-6 (2019)
Abstract Background The 2014 ACC/AHA guidelines redefined the strategy for LDL-cholesterol (LDL-C) treatment. According to data from evidence-based studies, the basis for earlier therapeutic recommendations for LDL-C target levels (2.6 and 1.8 mmol/L
Externí odkaz: https://doaj.org/article/b05dab955fa04a54a0ffedf1f80e0663
Zobrazit plný text záznamu
2
A kardiovaszkuláris történést jelző új európai SCORE2-rizikómodell és a kapcsolódó ESC-ajánlás lipidológiai tapasztalatai
Autor: Albert Császár
Publikováno v: Cardiologia Hungarica. 52:428-432
2003-ban megjelent SCORE1 volt az elsőként európai adatokra támaszkodó kardiovaszkuláris (CV) kockázatbecslő rendszer, amely lényeges előrelépést jelentett a primer prevenció területén a teendők indikációjának pontosítása szempon
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::41e97cdd394e03ff8376f4d54e4b0923
https://doi.org/10.26430/chungarica.2022.52.5.428
Zobrazit plný text záznamu
4
The characteristics of two LDL-cholesterol level reduction treatment strategies, 'treat-to-target' and 'percent reduction': an observational study without intervention
Autor: Albert Császár
Publikováno v: BMC Cardiovascular Disorders
BMC Cardiovascular Disorders, Vol 19, Iss 1, Pp 1-6 (2019)
Background The 2014 ACC/AHA guidelines redefined the strategy for LDL-cholesterol (LDL-C) treatment. According to data from evidence-based studies, the basis for earlier therapeutic recommendations for LDL-C target levels (2.6 and 1.8 mmol/L) may be
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab16540d641b212464362f1cd27f4573
https://pubmed.ncbi.nlm.nih.gov/30857520
Zobrazit plný text záznamu
5
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease
Autor: Armin Steinmetz, Michel Farnier, Kjetil Retterstøl, Albert Császár
Publikováno v: Diabetes and Vascular Disease Research. 9:205-215
Background: This study was designed to compare the efficacy and safety of a fenofibrate/pravastatin 160/40 mg fixed-dose combination plus ezetimibe 10 mg triple therapy and simvastatin 20 mg plus ezetimibe 10 mg dual therapy in patients with type 2 d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb6337bf0a59e5752d96db6e818ba9f0
https://doi.org/10.1177/1479164111430715
Zobrazit plný text záznamu
7
Toll-Like Receptors: Link between 'Danger' Ligands and Plaque Instability
Autor: Sándor Balogh, István Kiss, Albert Császár
Publikováno v: Current Drug Targets. 10:513-518
Myocardial infarction and stroke are exaggerated by rupture of atherosclerotic lesions. Rupture-sensitive plaques have a specific composition which renders them vulnerable, but additional factors (acute infection, higher sympathetic activity, excessi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::568f729055d3d35af66c51a9d1197348
https://doi.org/10.2174/138945009788488387
Zobrazit plný text záznamu
8
The Effect of Ciprofibrate on Flow-Mediated Dilation and Inflammatory Markers in Patients with Combined Hyperlipidemia
Autor: Jeno Tarján, Erzsébet Toldy, Imre Kovács, Tatjána Ábel, Albert Császár
Publikováno v: Endothelium. 12:179-183
Impairment of flow-mediated dilation (FMD) has been shown to be associated with hypercholesterolemia and hypertriglyceridemia and reduction of cholesterol and/or triglyceride levels can improve FMD. In hyperlipidemia the role of inflammatory substanc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13839890efbd6d1497a6d2ae38f0c585
https://doi.org/10.1080/10623320500227259
Zobrazit plný text záznamu
9
IL-6 AND LIPOPROTEIN (a) [LP(a)] CONCENTRATIONS ARE RELATED ONLY IN PATIENTS WITH HIGH APO(a) ISOFORMS IN MONOCLONAL GAMMOPATHY
Autor: Elöd László, Puskás E, Gabriella Halm, László Kalabay, László Romics, George Füst, Laura Horváth, Katalin Pálóczi, András Falus, Albert Császár, Hans Dieplinger, Anna Horváth, Aniko Banyai
Publikováno v: Cytokine. 18:340-343
We have investigated the influence of apo(a) genetics on the relationship between interleukin (IL)-6, and lipoprotein (a) [Lp(a)] levels in 154 patients with monoclonal gammopathy and 189 healthy subjects. No significant differences in Lp(a) levels a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ac252ad87441b64a3d95009d4c8559c
https://doi.org/10.1006/cyto.2002.1044
Zobrazit plný text záznamu
10
Association of plasma lipid levels with apolipoprotein E polymorphism in Type 2 diabetes
Autor: Albert Császár, Csaba Szalai, István Reiber, Ákos Kalina, Zoltán Prohászka
Publikováno v: Diabetes Research and Clinical Practice. 56:63-68
Objective: To evaluate the distribution of apolipoprotein E polymorphism in patients with Type 2 diabetes and their impact on plasma lipid levels. Subjects: Unrelated Type 2 diabetic patients (n=298) treated by diet and sulfonylurea and not receiving
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f897f7018ae2c9be5dceb0159033b04
https://doi.org/10.1016/s0168-8227(01)00350-3
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje